Key statistics
On Tuesday, Evaxion Biotech A/S (EVAX:NAQ) closed at 2.84, 25.66% above the 52 week low of 2.26 set on Jun 17, 2024.
52-week range
Open | 2.85 |
---|---|
High | 2.87 |
Low | 2.76 |
Bid | 2.60 |
Offer | 2.95 |
Previous close | 2.85 |
Average volume | 109.39k |
---|---|
Shares outstanding | 557.61k |
Free float | -- |
P/E (TTM) | -- |
Market cap | 15.84m USD |
EPS (TTM) | -36.98 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Announcements
- Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
- Evaxion significantly expands vaccine development collaboration with MSD
- Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
- Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
- Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
- Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results
- Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
- Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
- Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
More ▼